Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christy Finke

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
Haematologica|February 10, 2022
<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entityAbhishek A Mangaonkar, Terra L Lasho, Christy Finke, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Mayo Clinic Proceedings|June 6, 2018
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical InformationAyalew Tefferi, Naseema Gangat, Mythri Mudireddy, et al.
Blood|April 21, 2023
Spectrum of clonal hematopoiesis in VEXAS syndromeFernanda Gutierrez-Rodrigues, Yael Kusne, Jenna Fernandez, et al.
American Journal of Hematology|June 9, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating AgentsSaubia Fathima, Margaret Mei-Kay Wong, Jesus Gonzalez-Lugo, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
American Journal of Hematology|November 20, 2022
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patientsAbhishek A Mangaonkar, Kimberly J Langer, Terra L Lasho, et al.
British Journal of Haematology|March 5, 2020
Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)Guadalupe Antelo, Abhishek A Mangaonkar, Giacomo Coltro, et al.
Haematologica|February 10, 2022
<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entityAbhishek A Mangaonkar, Terra L Lasho, Christy Finke, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Mayo Clinic Proceedings|June 6, 2018
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical InformationAyalew Tefferi, Naseema Gangat, Mythri Mudireddy, et al.
Blood|April 21, 2023
Spectrum of clonal hematopoiesis in VEXAS syndromeFernanda Gutierrez-Rodrigues, Yael Kusne, Jenna Fernandez, et al.
American Journal of Hematology|June 9, 2026
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating AgentsSaubia Fathima, Margaret Mei-Kay Wong, Jesus Gonzalez-Lugo, et al.
Pageof 6